EMA Environmental Risk Assessment (ERA) Compliance In 2026: Complete Guide For Pharmaceutical Companies

Understanding EMA's Environmental Risk Assessment Requirements, Marketing Authorization Obligations, and Sustainable Regulatory Strategies Across the European Union

As environmental sustainability becomes an increasingly important component of pharmaceutical regulation, Environmental Risk Assessment (ERA) has evolved from a regulatory requirement into a strategic element of product development and lifecycle management.

By 2026, the European Medicines Agency's (EMA) updated Environmental Risk Assessment (ERA) Guideline has become an established expectation for companies seeking marketing authorization for human medicinal products across the European Union.

The guideline places greater emphasis on scientific robustness, environmental stewardship, transparency, and risk mitigation, ensuring that the potential environmental impact of medicinal products is evaluated throughout their lifecycle.

For pharmaceutical manufacturers, regulatory affairs professionals, environmental scientists, and market access teams, integrating ERA into development strategies is now essential for efficient regulatory submissions and long-term compliance.

Failure to adequately address ERA requirements can result in:

• Marketing authorization delays
• Regulatory questions and deficiency letters
• Additional data requests
• Extended review timelines
• Increased development costs
• Environmental compliance risks
• Submission inconsistencies
• Delayed market access
• Reputational impact

As environmental expectations continue to evolve across Europe, organizations that proactively integrate ERA into regulatory planning are better positioned to support sustainable product development and successful commercialization.

Executive Overview

Environmental Risk Assessment (ERA) evaluates the potential impact of pharmaceutical substances on the environment following their use and disposal.

The assessment considers how active pharmaceutical ingredients may affect:

• Surface water
• Groundwater
• Soil
• Aquatic organisms
• Terrestrial ecosystems
• Biodiversity
• Environmental persistence
• Bioaccumulation

Under the current EMA framework, ERA forms an integral component of Marketing Authorization Applications (MAAs) for human medicinal products submitted through:

Manufacturers must evaluate:

• Active substance characteristics
• Predicted environmental exposure
• Environmental fate
• Ecotoxicological profile
• Persistence and degradation
• Bioaccumulation potential
• Risk mitigation measures
• Supporting scientific evidence

Increasingly, pharmaceutical organizations are integrating ERA planning into early development programs rather than treating it solely as a submission requirement.

Environmental Sustainability Through Lifecycle Regulatory Planning

Why Environmental Risk Assessment Matters More Than Ever

Environmental protection has become an increasingly important objective within pharmaceutical regulation.

Medicinal products may enter the environment through:

• Patient excretion
• Manufacturing discharges
• Improper disposal
• Wastewater treatment systems
• Healthcare facility waste streams

Although medicines provide essential public health benefits, regulators increasingly expect manufacturers to understand and appropriately manage their potential environmental impacts.

ERA supports informed regulatory decision-making while contributing to broader sustainability initiatives across the European Union.

Environmental responsibility is now considered an important component of pharmaceutical product stewardship.

Understanding Environmental Risk Assessment (ERA)

An Environmental Risk Assessment evaluates whether pharmaceutical substances may pose unacceptable risks to environmental systems during their lifecycle.

Scientific evaluation typically includes assessment of:

• Physicochemical properties
• Environmental exposure estimates
• Environmental degradation
• Mobility in environmental compartments
• Ecotoxicity
• Bioaccumulation potential
• Persistence characteristics
• Risk characterization

The objective is to ensure that environmental risks remain appropriately managed while supporting continued patient access to innovative medicines.

Key Components of EMA ERA Requirements

1. ERA Requirements for Human Medicinal Products

By 2026, ERA has become a routine regulatory expectation for Marketing Authorization Applications involving human medicinal products.

ERA documentation is typically included within the regulatory dossier and should be scientifically justified using current guidance and available evidence.

Manufacturers should also evaluate whether lifecycle changes, including significant variations or expanded indications, require updates to previously submitted environmental assessments.

2. Two-Phase Risk Assessment Framework

EMA continues applying a structured, stepwise approach to environmental evaluation.

Phase I

The initial screening assesses whether predicted environmental exposure exceeds established action limits.

Evaluation includes:

• Estimated environmental concentrations
• Intended patient population
• Usage patterns
• Excretion estimates

Products with minimal environmental exposure may conclude assessment during Phase I.

Phase II

Where additional evaluation is warranted, Phase II provides a more comprehensive scientific assessment.

Typical studies include:

• Environmental fate investigations
• Biodegradation studies
• Chronic ecotoxicity assessments
• Environmental distribution analysis
• Risk characterization

Substances demonstrating higher environmental concern require more detailed scientific evaluation.

3. Greater Focus on Persistent Environmental Substances

One of the defining features of the current ERA framework is increased scrutiny of substances exhibiting:

• Persistence
• Bioaccumulation
• Toxicity
• Very persistent characteristics
• Very bioaccumulative properties

Manufacturers should carefully evaluate whether active substances demonstrate characteristics associated with:

• PBT (Persistent, Bioaccumulative and Toxic)
• vPvB (very Persistent, very Bioaccumulative)

Where appropriate, applicants should describe scientifically justified risk mitigation strategies within regulatory documentation.

4. Supporting the 3Rs Principle

The ERA framework continues supporting the European commitment to:

• Replacement
• Reduction
• Refinement
• of animal testing.

Applicants are encouraged to:

• Utilize validated alternative methods
• Leverage existing scientific literature
• Reuse publicly available data where scientifically appropriate
• Avoid unnecessary duplication of animal studies

These principles support both ethical research practices and regulatory efficiency.

5. Enhanced Scientific Transparency

Regulators increasingly encourage comprehensive use of:

• Published literature
• Historical study data
• Public databases
• Existing environmental evidence

Appropriate scientific justification and transparent documentation improve submission quality while reducing unnecessary testing.

Practical Implications for Pharmaceutical Companies

ERA should no longer be viewed as a standalone submission document.

Instead, it increasingly influences:

Organizations integrating environmental planning early within development programs often experience more efficient submission preparation.

Common Compliance Challenges

Manufacturers frequently encounter several avoidable challenges.

1. Delayed ERA Planning

Preparing ERA documentation late during submission development may create unnecessary regulatory delays.

2. Incomplete Scientific Justification

Insufficient environmental data may result in additional information requests during review.

3. Limited Cross-Functional Collaboration

Successful ERA preparation often requires coordination between:

• Regulatory Affairs
• Environmental Scientists
• Toxicologists
• Clinical Development
• CMC Teams

4. Inadequate Literature Utilization

Failure to leverage available scientific evidence may increase development costs and timelines.

5. Poor Lifecycle Integration

Environmental considerations should continue throughout the product lifecycle rather than end after initial approval.

Best Practices for Regulatory Success

Organizations should consider implementing proactive ERA strategies.

Integrate ERA into Early Development

Evaluation:

• Active substance characteristics
• Environmental exposure
• Product lifecycle
• Submission timelines
• Scientific data availability

Early planning improves regulatory efficiency.

Strengthening Scientific Documentation

Comprehensive documentation supports:

• Marketing Authorization Applications
• Regulatory responses
• Inspection readiness
• Lifecycle management
• Environmental transparency

Promote Cross-Functional Collaboration

Effective ERA programs involve close collaboration across:

• Regulatory Affairs
• Environmental Risk Specialists
• Clinical Teams
• Toxicology Experts
• Quality Functions

Integrated planning improves submission quality.

Maintain Regulatory Intelligence Programs

Manufacturers should continuously monitor:

• EMA guidance updates
• Scientific committee recommendations
• Environmental testing methodologies
• Sustainability initiatives
• Regulatory expectations

Regulatory intelligence supports long-term compliance and operational resilience.

Emerging Trends in Pharmaceutical Environmental Compliance

The future of pharmaceutical regulation increasingly combines scientific innovation with environmental responsibility.

Why Environmental Compliance Is Becoming a Competitive Advantage

Leading pharmaceutical organizations increasingly recognize ERA as more than a regulatory obligation.

It has become part of broader corporate sustainability strategies.

Companies with mature environmental compliance programs can:

• Improve submission readiness
• Reduce regulatory uncertainty
• Support ESG objectives
• Strengthen stakeholder confidence
• Improve operational efficiency
• Enhancing long-term market competitiveness

Environmental stewardship is becoming an important differentiator across the global pharmaceutical industry.

How Maven Regulatory Solutions Supports ERA Compliance

Our Expertise Includes

• Environmental Risk Assessment strategy
• ERA gap assessments
• Scientific literature reviews
• PBT and vPvB evaluations
• Ecotoxicology documentation support
• CTD Module 1.6 preparation
• Regulatory submission planning
• Lifecycle environmental compliance
• Regulatory intelligence monitoring

Why Companies Choose Maven

• Deep global regulatory expertise
• Science-based environmental assessments
• End-to-end regulatory support
• Scalable compliance frameworks
• Sustainability-focused regulatory strategies
• Cross-functional scientific expertise

Conclusion

By 2026, Environmental Risk Assessment has become an integral component of pharmaceutical regulatory strategy across the European Union.

The EMA ERA framework reinforces the importance of scientifically robust environmental evaluations, lifecycle compliance, transparency, and sustainable product development.

Organizations that proactively evaluate:

• Environmental exposure
• Substance persistence
• Ecotoxicological risks
• Scientific documentation
• Lifecycle compliance
• Regulatory intelligence

will be better positioned to achieve efficient marketing authorizations while supporting broader environmental sustainability objectives.

The strongest regulatory programs are no longer focused solely on product approval.

They integrate environmental responsibility as a strategic business asset that supports innovation, compliance, and sustainable growth.

FAQ

1. What is an Environmental Risk Assessment (ERA)?

An ERA evaluates the potential impact of a pharmaceutical substance on the environment throughout its lifecycle, including its effects on water, soil, and ecosystems.

2. Is an ERA required for all human medicinal products?

ERA is generally required as part of Marketing Authorisation Applications for human medicinal products in accordance with current EMA regulatory requirements.

3. What are PBT and vPvB substances?

These are substances that exhibit Persistence, Bioaccumulation, and Toxicity (PBT), or are very Persistent and very Bioaccumulative (vPvB), requiring enhanced environmental evaluation.

4. What is the purpose of the two-phase ERA approach?

The two-phase approach enables regulators to identify products requiring more detailed environmental assessment based on predicted environmental exposure and risk.

5. Why is ERA becoming increasingly important?

Environmental sustainability has become a core regulatory priority, making ERA an essential component of pharmaceutical development, regulatory submissions, and lifecycle management.